Form 4: CYTOKINETICS Director Sells Shares Under 10b5-1 Plan

CYTOKINETICS Director B. Lynne Parshall reported the sale of 5,000 shares of common stock for $64.73 per share, executed under a Rule 10b5-1 plan.

Summary

• B. Lynne Parshall, a Director at CYTOKINETICS INC (CYTK), reported a transaction involving the company's common stock.
• The transaction was a sale of 5,000 shares of common stock.
• The shares were sold at a price of $64.73 per share.
• The transaction date was 11/19/2025.
• Following this transaction, Ms. Parshall beneficially owns 22,933 shares of common stock.
• The sale was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of an insider stock sale under a Rule 10b5-1 plan, which is generally considered a routine event for personal liquidity management and does not inherently convey positive or negative sentiment about the company's performance.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

This Form 4 filing details a routine insider transaction by a director, which is a common occurrence in publicly traded companies. Such transactions, especially when conducted under a Rule 10b5-1 plan, are typically pre-scheduled and often relate to personal financial planning rather than a change in outlook on the company's prospects.

Stakeholder Impact

• Shareholders: The sale by a director could be interpreted in various ways, though a Rule 10b5-1 plan often mitigates concerns about insider sentiment. The transaction value is not exceptionally large relative to the company's market capitalization.

Key Dates

Keywords

CYTOKINETICS, CYTK, SEC Form 4, insider trading, stock sale, director transaction, Rule 10b5-1 plan